

NICU Pearls and Controversies



Authors:

Amy S. Lay, MD

*Director of Acute Care Cardiology
Regenstein Cardiac Care Unit
Attending Physician, Division of Pediatric Cardiology
Ann & Robert H. Lurie Children's Hospital of Chicago
Associate Professor of Pediatrics
Feinberg School of Medicine*
and

M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN

*Clinical Pharmacy Specialist – Neonatal Intensive Care Unit, Akron Children's Hospital
Professor – Pharmacy Practice
Director of Professional Development
Northeast Ohio Medical University
College of Pharmacy*

Disclosure(s): Dr. Lay and the reviewers who contributed to this activity have no relevant financial relationships of interest to disclose. Dr. M. Petrea Cober, a speaker, is a consultant for BBraun/CAPS, Baxter, Fresenius Kabi, and Lexi-Comp. All of the relevant financial relationships listed for this individual have been mitigated.

Purpose: To educate critical care providers on the current possible treatments for a patent ductus arteriosus (PDA) closure, when it is clinically applicable to close the PDA and what happens if medical treatment fails. To educate clinicians on the current evidence for neonatal refeeding syndrome in very-low birth weight premature infants, as well as prevention and treatment strategies for management. To educate clinicians on recent ASPEN guidelines involving the administration of parenteral nutrition and newer lipid injectable emulsions in neonatal/pediatric patients.

Learning Objectives:

Upon completion of this activity, participants should be able to:

- Describe the reasons to promote the closure of a ductus arteriosus in both very low birth weight preterm infants and full term infants
- Describe the agents available for pharmacologic closure of a patent ductus arteriosus
- Describe the interventional options (e.g., catheter based and surgical based) to close a patent ductus arteriosus
- Describe the risk factors for neonatal refeeding syndrome (RS) and strategies for prevention and treatment
- Summarize current evidence surrounding recent ASPEN guidelines for parenteral nutrition filtering requirements, photoprotection of parenteral nutrition, and the safe use of newer lipid injectable emulsion for neonatal patients

Target Audience: Physicians

Type of Activity: Knowledge

2022 participants who registered for the live program, please use the access code provided to you by email.

Release and Most Recent Review Date: September 30, 2022

Fee: \$10 (or \$70 for all 10 courses). For C4

Expiration Date: August 27, 2023

Estimated time to complete activity: 1.0 hour CME (1.0 AMA PRA Category 1 Credit)

Location: Please visit <https://medicinece.uic.edu/> to participate in this activity.

Continuing Medical Education Statement:



The University of Illinois College of Medicine at Chicago is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Illinois College of Medicine at Chicago designates this Enduring Material CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Earn Credit:

Participants must complete the activity as described above in the Continuing Medical Education Statement by viewing the entire presentation video and completing a post-test and an activity evaluation. A certificate of completion will be issued after all requirements as described are completed.

Hardware/Software and Internet Requirements can be found at <https://medicinece.uic.edu/>

Provider Contact Information: For general information please call the Office of Continuing Education and Meeting Services toll-free at (866) PHARM-CE (866-742-7623) or send an e-mail to: pharmce@uic.edu. Copyright © 2022 – The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. [Privacy Policy](#).